Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CLDI | PRESS-RELEASE | mixed | 5/10 | Calidi Biotherapeutics reported Q2 2026 results with a narrowed net loss of $4.2M ($2.94/share) vs $5.7M ($31.75/share) | Aug 13, 2026 |
| TIL | PRESS-RELEASE | neutral | 4/10 | Instil Bio reported Q2 2026 GAAP net loss of $0.63 per share, narrowing from a $3.24 loss in Q2 2025, driven by sharply | Aug 13, 2026 |
| TPST | PRESS-RELEASE | bearish | 7/10 | Tempest Therapeutics reported Q2 2026 net loss of $5.2M ($0.34/share), a narrower loss vs $7.9M ($2.07) a year ago, but | Aug 13, 2026 |
| INBX | PRESS-RELEASE | bearish | 6/10 | Inhibrx reported Q2 2026 EPS of -$2.34, a 26.5% miss vs the -$1.85 year-ago period, and zero revenue (vs $1.3M in Q2 202 | Aug 13, 2026 |
| NKTR | PRESS-RELEASE | bullish | 7/10 | Nektar Therapeutics reported Q2 2026 EPS of -$1.23, a 39.6% beat vs consensus of -$2.04, on revenue of $10.1M (slightly | Aug 13, 2026 |
| RNA | PRESS-RELEASE | neutral | 4/10 | Atrium Therapeutics reported Q2 2026 collaboration revenue of $3.0M, a net loss of -$1.18 per share, and highlighted FDA | Aug 13, 2026 |
| ASMB | PRESS-RELEASE | bullish | 6/10 | Assembly Biosciences reported Q2 2026 EPS of -$0.20, beating consensus of -$0.53 by 62.3%, and collaboration revenue of | Aug 13, 2026 |
| KOD | PRESS-RELEASE | neutral | 6/10 | Kodiak Sciences reported Q2 2026 net loss of $65.6M ($1.05/share), wider than the $54.3M loss in Q2 2025, with R&D spend | Aug 13, 2026 |
| QUCY | PRESS-RELEASE | neutral | 3/10 | Quantum Cyber published a whitepaper detailing its patent-pending Quantum Photonic Antenna architecture, an early-stage | Aug 13, 2026 |
| CMND | PRESS-RELEASE | bullish | 6/10 | Clearmind Medicine received DSMB approval to advance its Phase I/II trial of CMND-100 for Alcohol Use Disorder to Parts | Aug 13, 2026 |
| CADL | PRESS-RELEASE | bullish | 7/10 | Candel Therapeutics reported Q2 2026 financial results with a net loss of $38.9M ($0.52 per share), significantly wider | Aug 13, 2026 |
| MGTX | PRESS-RELEASE | neutral | 5/10 | MeiraGTx reported Q2 2026 GAAP net income of $160.7M ($1.71 diluted EPS) vs a net loss of $38.8M ($-0.48) a year ago, dr | Aug 13, 2026 |
| GRCE | PRESS-RELEASE | mixed | 5/10 | Grace Therapeutics reported a net loss of $15.8M for Q1 FY2027 (June 30, 2026), driven by a $13.5M impairment of IPR&D f | Aug 13, 2026 |
| ARTL | PRESS-RELEASE | neutral | 4/10 | Artelo Biosciences reported Q2 2026 net loss of $2.4M ($0.89/share) vs $3.2M in Q2 2025, with R&D expenses halved to $0. | Aug 13, 2026 |
| ASND | PRESS-RELEASE | bullish | 7/10 | Ascendis Pharma reported Q2 2026 product revenue of €315M (+105% YoY), driven by YORVIPATH (€252M) and SKYTROFA (€55M), | Aug 13, 2026 |
| CLRB | PRESS-RELEASE | neutral | 4/10 | Cellectar Biosciences reported Q2 2026 net loss of $6.9M ($0.57/share) vs $5.4M ($3.39/share) in Q2 2025, with R&D spend | Aug 13, 2026 |
| ABEO | PRESS-RELEASE | mixed | 6/10 | Abeona reported Q2 2026 net ZEVASKYN revenue of $11.4M, up 31% QoQ, with five patients treated. However, EPS of -$0.35 m | Aug 13, 2026 |
| CRMD | PRESS-RELEASE | neutral | 5/10 | No summary provided | Aug 13, 2026 |
| NGEN | PRESS-RELEASE | neutral | 5/10 | NervGen Pharma reported Q2 2026 EPS of -$0.06, beating consensus of -$0.07 by 9.8%, but the company remains pre-revenue | Aug 13, 2026 |
| FTLF | PRESS-RELEASE | mixed | 5/10 | FitLife Brands reported Q2 2026 revenue of $26.5M (+65% YoY, beating $26.0M consensus) but diluted EPS of $0.20 missed t | Aug 13, 2026 |
| CABA | PRESS-RELEASE | neutral | 4/10 | Cabaletta Bio reported Q2 2026 EPS of -$0.34, beating consensus of -$0.37 by 8.1%, with no revenue. The company highligh | Aug 13, 2026 |
| INKT | PRESS-RELEASE | mixed | 6/10 | MiNK Therapeutics reported Q2 2026 net loss of $3.1M ($0.62/share), improving from $4.2M ($1.06/share) in Q2 2025, with | Aug 13, 2026 |
| PULM | PRESS-RELEASE | bearish | 6/10 | Pulmatrix reported Q2 2026 financial results with minimal revenue, a net loss of $1.0M, and a cash burn that reduced its | Aug 13, 2026 |
| OTLK | PRESS-RELEASE | bearish | 7/10 | Outlook Therapeutics priced a dilutive underwritten public offering of 55.6M shares and warrants at $0.99/unit, raising | Aug 12, 2026 |
| BLTE | PRESS-RELEASE | bullish | 7/10 | Belite Bio reported Q2 2026 GAAP EPS of -$0.70, a miss vs consensus of -$0.78 (12.5% beat on a loss-per-share basis, but | Aug 12, 2026 |
| AEON | PRESS-RELEASE | neutral | 4/10 | AEON Biopharma reported Q2 2026 EPS of -$0.02, significantly beating the consensus estimate of -$0.33, though this is a | Aug 12, 2026 |
| TRAX | PRESS-RELEASE | bullish | 6/10 | First Tracks Biotherapeutics reported Q2 2026 net loss of $33.4M ($0.95/share), narrower than the $42.4M loss in Q2 2025 | Aug 12, 2026 |
| RVPH | PRESS-RELEASE | neutral | 4/10 | Reviva Pharmaceuticals reported Q2 2026 net loss of $2.4M ($0.19/share), narrower than the $6.1M loss in Q2 2025, but EP | Aug 12, 2026 |
| AZTR | PRESS-RELEASE | bearish | 6/10 | Azitra reported Q2 2026 EPS of -$0.17, a miss vs consensus of -$0.23, with net loss widening to $3.3M from $2.9M YoY. Th | Aug 12, 2026 |
| MTEX | PRESS-RELEASE | bullish | 6/10 | Mannatech reported Q2 2026 net sales of $26.7M, up $1.0M YoY, and swung to net income of $1.0M ($0.53/diluted share) fro | Aug 12, 2026 |